Search Results 801-810 of 17059 for egfr

  1. Publications - Isabel O. Cortopassi, M.D. - Mayo Clinic

    EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. Ann Oncol. 2019; 30(8):1311-1320.. Haas BM, Hahn ...

  2. A Study of Ibubilast in Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    ... eGFR < 30 mL/min/1.73m2, thyroid-stimulating hormone (TSH) levels >10 mIU/L or <0.01 mIU/L. 3. Active drug or alcohol abuse 4. Female patient is lactating ...

  3. A Study to Evaluate Abemaciclib to Treat Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration - Mayo Clinic

    Estimated Creatinine Clearance (CrCl) ≥ 30 mL/min (Cockcroft-Gault), estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m^2 (MDRD or CKD-EPI ...

  4. Hyperoxaluria And Oxalosis Clinical Trials - Mayo Clinic Research

    ... eGFR and serum creatinine. A Study of the Potential for Polyethylene Glycol (Miralax) to Metabolize into Toxic Oxalate Rochester, MN. The purpose of this ...

  5. A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis - Mayo Clinic

    Estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m^2 at screening. Exclusion Criteria: Known or suspected hypersensitivity to study ...

  6. (HARBOR) Study To Evaluate Efficacy And Safety Of BLU-263 Versus Placebo In Patients With Indolent Systemic Mastocytosis - Mayo Clinic

    Estimated glomerular filtration rate (eGFR; calculated using the Modification of Diet in Renal Disease equation) < 30 mL/min/1.73 m^2 or creatinine > 1.5 × ULN.

  7. Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus - Mayo Clinic

    Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value < 60 mL/min 27. Concomitant treatment with PPAR-? agonists (fibrates) 28 ...

  8. A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD) - Mayo Clinic

    The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal ...

  9. A Study to Evaluate the Intrarenal Microvessels in Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

    The primary objective of this study is to evaluate the use of Super-resolution ultrasound (SRU) to assess the intrarenal microvasculature in patients with ...

  10. Fenofibrate for Prevention of DR Worsening - Mayo Clinic

    Decreased renal dysfunction, defined as requiring dialysis or central laboratory eGFR value < 60. Active liver disease, defined as any liver function test > ...